Setipiprant, also known as ACT-129968 and KYTH-105, is a potent and selective CRTH2 antagonist. Setipiprant at multiple oral doses was well tolerated and reduced both the allergen-induced LAR and the associated AHR in allergic asthmatics. Our findings confirm that CRTH2 may be a promising target for the treatment of allergic disorders.
Prostaglandin Receptor Related Products:
E-7046; Ramatroban; Ozagrel; Bimatoprost; Prostaglandin E2; Tafluprost; Carboprost; Treprostinil sodium; MRE-269; Travoprost; Misoprostol; Selexipag